<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04194450</url>
  </required_header>
  <id_info>
    <org_study_id>H19-02947</org_study_id>
    <nct_id>NCT04194450</nct_id>
  </id_info>
  <brief_title>Exogenous Ketones in Type 2 Diabetes</brief_title>
  <official_title>The Effect of Acute Exogenous Oral Ketone Supplementation on Blood Glucose Levels in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exogenous ketone supplements are proposed to have glucose-lowering potential, provide an
      alternative fuel for the brain and to enhance cognitive function. No studies have tested
      whether exogenous ketones can lower blood glucose in people with type 2 diabetes. In
      addition, the impact of exogenous ketones on brain blood flow, cognitive function or
      brain-derived neurotrophic factor in humans is unknown. The purpose of this study is to
      determine if acutely ingesting exogenous ketones, in the form of a ketone monoester drink,
      can lower glucose and improve measures of brain/cognitive function in humans with type 2
      diabetes. Participants will consume a ketone monoester drink or placebo with blood samples,
      brain blood flow, and cognitive function assessed over 180 minutes. The researchers will also
      test how the ketone monoester drink impacts appetite and measures of inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo masked with flavouring and participants consume in opaque containers.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>180 minutes</time_frame>
    <description>Plasma glucose concentration after ketone or placebo ingestion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma insulin</measure>
    <time_frame>180 minutes</time_frame>
    <description>Insulin across concentration after ketone or placebo ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma C-peptide</measure>
    <time_frame>180 minutes</time_frame>
    <description>C-peptide across concentration after ketone or placebo ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma free fatty acids</measure>
    <time_frame>180 minutes</time_frame>
    <description>Non-esterified fatty acid concentration after ketone or placebo ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma tumour necrosis factor alpha</measure>
    <time_frame>180 minutes</time_frame>
    <description>Plasma tumour necrosis factor alpha concentration after ketone or placebo ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma tumour interleukin-1beta</measure>
    <time_frame>180 minutes</time_frame>
    <description>Plasma tumour interleukin-1beta concentration after ketone or placebo ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma tumour interleukin-6</measure>
    <time_frame>180 minutes</time_frame>
    <description>Plasma tumour interleukin-6 concentration after ketone or placebo ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral blood flow</measure>
    <time_frame>180 minutes</time_frame>
    <description>Intracranial blood flow velocity measured by ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>180 minutes</time_frame>
    <description>Blood pressure measured manually and by Finipres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>180 minutes</time_frame>
    <description>Measures of cognitive function using Brain Baseline battery on an iPad.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain-derived neurotrophic factor</measure>
    <time_frame>180 minutes</time_frame>
    <description>Brain-derived neurotrophic factor concentrations after ketone or placebo ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood monocytes</measure>
    <time_frame>180 minutes</time_frame>
    <description>Total blood monocytes and monocyte subsets after ketone or placebo ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self reported hunger and fullness</measure>
    <time_frame>180 minutes</time_frame>
    <description>Self reported hunger and fullness by a 0 to 100 mm Visual Analog Scale (higher scores mean greater hunger or fullness)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal symptoms</measure>
    <time_frame>180 minutes</time_frame>
    <description>Gastroinestinal symptom questionnaire scores after ketone or placebo ingestion on a 0 to 100 mm Visual Analog Scale (higher scores mean greater symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total energy consumed</measure>
    <time_frame>180 minutes after ketone or placebo ingestion</time_frame>
    <description>Total energy consumed in kilocalories in buffet style meal after ketone or placebo ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocyte histone acetylation</measure>
    <time_frame>180 minutes</time_frame>
    <description>Histone acetylation status of monocytes measured after ketone or placebo ingestion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ketosis</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Ketone monoester</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.3 ml/kg body weight)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Acute dose of flavour-matched placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ketone monoester</intervention_name>
    <description>Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior to assessment of outcomes.</description>
    <arm_group_label>Ketone monoester</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Acute ingestion of taste-matched placebo prior to assessment of outcomes.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  physician-diagnosed type 2 diabetes of ≥1 year

          -  current hemoglobin A1C (HbA1c) of 6.5-8.0%

          -  treatment with lifestyle or stable (≥3 months) oral glucose-lowering medications

          -  blood pressure of &lt;160/99 mm Hg assessed according to guidelines

          -  non-smoking

          -  no prior history of cardiovascular disease or stroke

          -  not on hormone replacement therapy, corticosteroids, or anti-inflammatory medications

          -  20-75 years old

        Exclusion Criteria:

          -  being a competitive endurance athlete

          -  taking exogenous insulin or sodium glucose transporter 2 (SGLT2) inhibitors

          -  following a ketogenic diet, low-calorie diet, periodic fasting regimen, or consume
             ketogenic supplements

          -  being unable to travel to and from the university

          -  being unable to follow the controlled diet instructions

          -  being pregnant or planning to become pregnant during the study (if female)

          -  disorders of fat metabolism, chronic pancreatitis, had gastric bypass surgery and/or
             gallbladder disease

          -  being unable to read or communicate in English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan Little, PhD</last_name>
    <phone>2508079876</phone>
    <email>jonathan.little@ubc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara Oliveira, PhD, RD</last_name>
    <email>barbara.oliveira@ubc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of British Columbia, Okanagan</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1V 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Little, PhD</last_name>
      <phone>2508079876</phone>
      <email>jonathan.little@ubc.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Jonathan Little</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

